3′,4′,5′-Trimethoxy- and 3,4-Dimethoxychalcones Targeting A549 Cells: Synthesis, Cytotoxic Activity, and Molecular Docking

[1]  W. Chavasiri,et al.  Tetrahydroxanthone-chromanone heterodimers from lichen Usnea aciculifera and their cytotoxic activity against human cancer cell lines. , 2020, Fitoterapia.

[2]  T. Rungrotmongkol,et al.  Enhanced Solubility and Anticancer Potential of Mansonone G By β-Cyclodextrin-Based Host-Guest Complexation: A Computational and Experimental Study , 2019, Biomolecules.

[3]  T. Rungrotmongkol,et al.  Atomistic mechanisms underlying the activation of the G protein-coupled sweet receptor heterodimer by sugar alcohol recognition , 2019, Scientific Reports.

[4]  M. Ramadan,et al.  Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors. , 2019, Bioorganic & medicinal chemistry.

[5]  T. Rungrotmongkol,et al.  Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors , 2019, Molecules.

[6]  Riham F. George,et al.  Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors. , 2019, Bioorganic chemistry.

[7]  A. Kamal,et al.  Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors. , 2019, European journal of medicinal chemistry.

[8]  Megha Jagadale,et al.  Anticancer activity of ruthenocenyl chalcones and their molecular docking studies , 2018, Journal of Molecular Structure.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  K. Shah,et al.  Synthesis and investigations into the anticancer and antibacterial activity studies of β-carboline chalcones and their bromide salts. , 2018, Bioorganic & medicinal chemistry letters.

[11]  A. Saxena,et al.  Synthesis and Characterization of Chalcone‐Pyridinium Hybrids as Potential Anti‐Cancer and Anti‐Microbial Agents , 2018 .

[12]  Rafał Kurczab,et al.  Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents. , 2018, European journal of medicinal chemistry.

[13]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[14]  Hany E. A. Ahmed,et al.  Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects , 2017, Molecules.

[15]  S. N. Bukhari,et al.  Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells. , 2016, Journal of medicinal chemistry.

[16]  L. Borsu,et al.  Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. , 2015, JAMA oncology.

[17]  C. Xing,et al.  Diverse Molecular Targets for Chalcones with Varied Bioactivities , 2015, Medicinal chemistry.

[18]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[19]  Yong-Yeon Cho,et al.  Isoliquiritigenin Induces Apoptosis and Inhibits Xenograft Tumor Growth of Human Lung Cancer Cells by Targeting Both Wild Type and L858R/T790M Mutant EGFR* , 2014, The Journal of Biological Chemistry.

[20]  H. Lou,et al.  Synthesis and biological evaluation of Combretastatin A-4 derivatives containing a 3’-O-substituted carbonic ether moiety as potential antitumor agents , 2013, Chemistry Central Journal.

[21]  A. Misra,et al.  Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. , 2013, Biomaterials.

[22]  R. Yunes,et al.  Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors. , 2013, European journal of medicinal chemistry.

[23]  M. Ladanyi,et al.  Characteristics of Lung Cancers Harboring NRAS Mutations , 2013, Clinical Cancer Research.

[24]  K. Borden,et al.  Mechanisms and insights into drug resistance in cancer , 2013, Front. Pharmacol..

[25]  Thokhir Basha Shaik,et al.  Synthesis of chalcone-amidobenzothiazole conjugates as antimitotic and apoptotic inducing agents. , 2012, Bioorganic & medicinal chemistry.

[26]  Jun Du,et al.  Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNFα-induced nuclear factor-κB activation inhibition. , 2012, European journal of medicinal chemistry.

[27]  A. Gemma,et al.  F1000 highlights , 2010 .

[28]  M. Bonesi,et al.  The synthesis and angiotensin converting enzyme (ACE) inhibitory activity of chalcones and their pyrazole derivatives. , 2010, Bioorganic & medicinal chemistry letters.

[29]  C. Khobragade,et al.  Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents. , 2010, Bioorganic & medicinal chemistry.

[30]  Y. Tzeng,et al.  Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation. , 2009, Bioorganic & medicinal chemistry.

[31]  N. Lawrence,et al.  Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. , 2009, Bioorganic & medicinal chemistry.

[32]  B. Srinivasan,et al.  Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities. , 2009, Journal of medicinal chemistry.

[33]  M. Ninova,et al.  Examination of growth inhibitory properties of synthetic chalcones for which antibacterial activity was predicted. , 2009, European journal of medicinal chemistry.

[34]  D. Hadjipavlou-Litina,et al.  Chalcones in cancer: understanding their role in terms of QSAR. , 2009, Current medicinal chemistry.

[35]  F. Monache,et al.  Structure-activity relationship of antibacterial chalcones. , 2008, Bioorganic & medicinal chemistry.

[36]  D. Gewirtz,et al.  Colchicine site inhibitors of microtubule integrity as vascular disrupting agents , 2008 .

[37]  M. Meyerson,et al.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.

[38]  C. Hung,et al.  Synthesis and cytotoxic, anti-inflammatory, and anti-oxidant activities of 2',5'-dialkoxylchalcones as cancer chemopreventive agents. , 2008, Bioorganic & medicinal chemistry.

[39]  A. Brancale,et al.  Design, synthesis, and biological evaluation of thiophene analogues of chalcones. , 2008, Bioorganic & medicinal chemistry.

[40]  H. Wakelee,et al.  Review of erlotinib in the treatment of advanced non-small cell lung cancer , 2007, Biologics : targets & therapy.

[41]  G. Achanta,et al.  A Boronic-Chalcone Derivative Exhibits Potent Anticancer Activity through Inhibition of the Proteasome , 2006, Molecular Pharmacology.

[42]  N. Davidson,et al.  Anticancer activities of novel chalcone and bis-chalcone derivatives. , 2006, Bioorganic & medicinal chemistry.

[43]  D. Alberts,et al.  Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 , 1989, Experientia.

[44]  Charles L. Brooks,et al.  Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..

[45]  N. Davidson,et al.  Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. , 2003, Journal of medicinal chemistry.

[46]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[47]  J. Minna,et al.  Molecular pathogenesis of lung cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[48]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[49]  D. Sackett.  Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. , 1993, Pharmacology & therapeutics.

[50]  S. Yamamoto,et al.  The potent anti-tumor-promoting agent isoliquiritigenin. , 1991, Carcinogenesis.

[51]  M. L. Edwards,et al.  Chalcones: a new class of antimitotic agents. , 1990, Journal of medicinal chemistry.